The age of HAE onset varies. Most people with HAE first experience symptoms in childhood.

Studies suggest that:

  • 50% of people with HAE first experience an attack before age 10
  • Most people have experienced their first attack before 18 years of age
  • Around 10% of people with HAE report initial symptoms between age 18-25
  • HAE attacks have been reported in children as early as one (1) year of age

HAE attacks are generally infrequent in young children, and symptoms are usually mild. The frequency and severity of HAE attacks typically increase during puberty and adolescence.

Without treatment, people with HAE continue to experience attacks throughout their lives.

HAE can be successfully managed with effective preventative (prophylaxis) and on-demand (acute) treatment. When people with HAE can access modern therapies to manage their HAE, their quality of life improves.

>> Read more about how HAE can be treated

The age of HAE onset varies. Most people with HAE first experience symptoms in childhood. [Zuraw 2010]

Studies suggest that:

  • 50% of people with HAE first experience an attack before age 10 [Zuraw 2010]
  • Most people have experienced their first attack before 18 years of age [Banerji 2015]
  • Around 10% of people with HAE report initial symptoms between age 18-25 [Banerji 2015]
  • HAE attacks have been reported in children as early as one (1) year of age [Zuraw 2010]

HAE attacks are generally infrequent in young children, and symptoms are usually mild. [MacGinnitie 2014] The frequency and severity of HAE attacks typically increase during puberty and adolescence. [MacGinnitie 2014]

Without treatment, people with HAE continue to experience attacks throughout their lives.

HAE can be successfully managed with effective preventative (prophylaxis) and on-demand (acute) treatment. When people with HAE can access modern therapies to manage their HAE, their quality of life improves. [Castaldo 2020]

—

Zuraw 2010: Zuraw BL. The pathophysiology of hereditary angioedema. World Allergy Organ J. 2010 Sep;3(9 Suppl):S25-8. doi: 10.1097/WOX.0b013e3181f3f21c. PMID: 23282866; PMCID: PMC3666152.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666152/ [Free full text]

Banerji 2015: Banerji A, Busse P, Christiansen SC et al. Current state of hereditary angioedema management: a patient survey. Allergy Asthma Proc. 2015 May-Jun;36(3):213-7. doi: 10.2500/aap.2015.36.3824. PMID: 25976438; PMCID: PMC4405601.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405601/ [Free full text]

MacGinnitie 2014: MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014 Aug;25(5):420-7. doi: 10.1111/pai.12168. Epub 2013 Dec 9. PMID: 24313851; PMCID: PMC4282351.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282351/ [Free full text]

Castaldo 2020: Castaldo AJ, Jervelund C, Corcoran D et al. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema. Allergy Asthma Proc. 2021 Mar 13;42(2):108-117. doi: 10.2500/aap.2021.42.200127. Epub 2021 Feb 13. PMID: 33581742; PMCID: PMC8133018.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133018/ [Free full text]